Announcements Trials
Browse Landscape

Phase

Phase 2 20Phase 3 11Phase EARLY_PHASE1 2Phase 1 2Phase NA 1Phase 1/2 1

Status

Completed 8Unknown 5Terminated 1Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

HR Positive HER2 Negative Advanced Breast Cancer 1

Interventions

Blood Specimen Collection 106Standard of Care 82Exercise 68Radiotherapy 54Radiosurgery 47Magnetic Resonance Spectroscopy 46Specimen Handling 45Practice Guidelines as Topic 44Surveys and Questionnaires 43Interviews as Topic 43Educational Status 42Methods 41Drug Therapy 34Early Intervention, Educational 30Surgical Procedures, Operative 29Palliative Care 25Biopsy 24Control Groups 21venetoclax 17Therapeutics 17Patient Navigation 17Cisplatin 17Proton Therapy 15Magnetic Resonance Imaging 15Behavior Therapy 15Neoadjuvant Therapy 14Cognitive Behavioral Therapy 13Acupuncture Therapy 13Resistance Training 12Nutritional Status 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase NA × Recruiting × Tamoxifen × Clear all
NCT05890287 2023-06-06

A Study of Chidamide Plus Endocrine in Maintenance Treatment of HR+/HER2- Breast Cancer After First-line Chemotherapy

Tianjin Medical University Cancer Institute and Hospital

Phase NA Recruiting
60 enrolled
Breast

HR Positive HER2 Negative Advanced Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡